E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Dry eye disease |
Enfermedad del ojo seco |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease |
Conocer la eficacia y seguridad del empleo de colirio de insulina en el control de la enfermedad de ojo seco moderada-grave |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients older than 18 years Signed informed consent by the patient Corneal staining equal to or greater than Oxford II OSDI greater than 12 Treatment with artificial tears or hyaluronic acid gels for at least 3 months |
Pacientes mayores de 18 años Firma del consentimiento informado por parte del paciente Tinción corneal igual o mayor a Oxford II OSDI mayor de 12 Tratamiento con lágrima artificial y/o gel de ácido hialurónico durante al menos 3 meses |
|
E.4 | Principal exclusion criteria |
Under 18 years old Corneal staining under Oxford II OSDI below 13 Changes in topical treatment in the last 3 months Eye surgery in the last 6 months Other concomitant corneal pathology, eyelid malpositions, nasolacrimal drainage abnormalities, blinking alterations Contact lenses Systemic pathology (cardiopulmonary pathology, connective tissue disorders, neurological or psychiatric pathology) or baseline situation of the patient that does not allow the examination (such as mental or psychomotor retardation) Other treatment besides artificial tears or hyaluronic acid gels Visual acuity less than 0.1 Allergy or intolerance to any of the components included in the study Modifications in systemic immunosuppressive treatment Pregnancy or lactation Women of childbearing age who do not use a highly effective contraceptive method History of alcohol or drug abuse Participation in another clinical trial in the last 30 days |
Menores de 18 años Tinción corneal menor de Oxford II OSDI menor de 13 Cambios en el tratamiento tópico en los últimos 3 meses Cirugía ocular en los últimos 6 meses Otra patología corneal concomitante, malposición palpebral, alteraciones del drenaje nasolagrimal, alteraciones del parpadeo Uso de lentes de contacto Patología sistémica (patología cardiopulmonar, alteraciones del tejido conectivo, patología neurológica o psiquiátrica) o situación basal del paciente que no permita la realización de la exploración (como retraso mental o psicomotor) Otro tratamiento distinto de lágrima artificial y/o gel de ácido hialurónico Agudeza visual menor de 0.1 Alergia o intolerancia a alguno de los componentes incluidos en el estudio Modificaciones en el tratamiento inmunosupresor sistémico Embarazo o lactancia Mujeres en edad fértil que no empleen un método anticonceptivo de alta efectividad Antecedentes de abuso de alcohol o drogas Participación en otro ensayo clínico en los últimos 30 días |
|
E.5 End points |
E.5.1 | Primary end point(s) |
No corneal staining |
No tinción corneal |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1, 3 and 6 months after starting treatment |
1, 3 y 6 meses tras iniciar tratamiento |
|
E.5.2 | Secondary end point(s) |
Improvement in dry eye symptoms, esthesiometry, and tear rupture time |
Mejoría en los síntomas de ojo seco, estesiometría y el tiempo de ruptura lagrimal |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1, 3 and 6 months after starting treatment |
1, 3 y 6 meses tras iniciar tratamiento |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Lágrima artificial |
Artificial tears |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |